Asthma/COPD Pharmacology (Young)

36 Questions | Total Attempts: 2206

SettingsSettingsSettings
Please wait...
Asthma/COPD Pharmacology (Young)

There are two ways to manage asthma which include preventing the symptoms or treating the symptoms by using inhalers which for the two main reasons. The quiz below is set to test out what you have understood through your classes about dosage and drugs prescribed to an asthma patient. Give it a try!


Questions and Answers
  • 1. 
    Drug treatment for asthma and COPD aim to do all of the following except:
    • A. 

      Cure asthma/COPD

    • B. 

      Relieve/prevent bronchoconstriction

    • C. 

      Inhibit airway inflammation

    • D. 

      Prevent airway remodeling

    • E. 

      Manage asthma/COPD

  • 2. 
    Stimulation of beta-2 sympathetic receptors can alleviate bronchoconstriction. Drugs that stimulate these receptors are called all of the following except:
    • A. 

      Sympathomimetics

    • B. 

      Adrenergics

    • C. 

      Beta-2 agonist

    • D. 

      Catecholamines

    • E. 

      Alpha-1 antagonists

  • 3. 
    Beta-adrenergic stimulation by agonists stimulate AC to increase cAMP. The increase in cAMP correctly affects which of the following pathways?
    • A. 

      PKA stimulating MLCK

    • B. 

      PKA inhibiting MLCK

    • C. 

      PLC stimulating MLC

    • D. 

      PLC inhibiting MLC

    • E. 

      All of the above pathways are affected by beta-adrenergic agonists

  • 4. 
    The binding of cAMP to the regulatory subunits of PKA liberate 2 catalytic subunits. What is the mechanism of action of these catalytic subunits?
    • A. 

      Phosphorylation of MLC to inhibit airway muscles

    • B. 

      Phosphorylation of MLCK to inhibit airway muscles

    • C. 

      Phosphorylation of PKA to inhibit MLCK

    • D. 

      Phosphorylation of PKA to inhibit MLC

    • E. 

      None of the above are the correct mechanism of action of these catalytic subunits

  • 5. 
    Primarily, beta-2 adrenergic agonist alleviate bronchoconstriction. Additional potential benefits include all of the following except:
    • A. 

      Reduce plasma exudation

    • B. 

      Increase ciliary action

    • C. 

      Mast cell stabilization

    • D. 

      Reduce bacterial adherence to epithelial cells

    • E. 

      All of the above are additional benefits of beta-2-agonists

  • 6. 
    Which of the following pairs are the NON-selective beta-2-agonists?
    • A. 

      Ephedrine and albuterol

    • B. 

      Isoproterenol and pirbuterol

    • C. 

      Ephedrine and isoproterenol

    • D. 

      Albuterol and pirbuterol

    • E. 

      Salmeterol and formoterol

  • 7. 
    Beta-2-agonists, can be administered in all of the following mechanisms of action except:
    • A. 

      Inhalation solutions

    • B. 

      Long acting, oral agents

    • C. 

      Intravenous agents

    • D. 

      Inhaled dry powders

    • E. 

      All of the above are routes of administration of beta-2-agonists

  • 8. 
    True or False: When using intravenous formulations of beta-2-agonists, a smaller dose is necessary compared to inhaled formulations.
    • A. 

      True

    • B. 

      False

  • 9. 
    Side effects of beta-2-agonists include all of the following except:
    • A. 

      Tremors

    • B. 

      Headaches

    • C. 

      Tachycardia

    • D. 

      Bradycardia

    • E. 

      Hypertension

  • 10. 
    Levalbuterol is the r-enantiomer of the racemic mixture of albuterol. This formulation is thought to exhibit _____ selectivity of the ____ receptor, contributing to fewer side effects. 
    • A. 

      Lower; B1

    • B. 

      Lower; B2

    • C. 

      Higher; B1

    • D. 

      Higher; B2

    • E. 

      None of the above pairs are correct

  • 11. 
    Long acting beta agonists have a unique structural feature that make them long-acting. What is this unique structural feature?
    • A. 

      High number of hydrophilic OH groups

    • B. 

      Presence of the highly water soluble nitrogen atom

    • C. 

      Long hydrophobic carbon tails

    • D. 

      High number of hydrophobic phenolic rings

    • E. 

      All of the above contribute to the LABA activity

  • 12. 
    The S.M.A.R.T exhibited asthma related deaths due to Salmeterol. Which one of the following reason is NOT attributed to these asthma related deaths?
    • A. 

      Salmeterol masks underlying inflammation

    • B. 

      Salmeterol was misused during an acute asthma attack

    • C. 

      Salmeterol partial agonist nature interfered with SABA's during an acute attack

    • D. 

      Salmeterol causes more sides effects, tachycardia and muscle tremor, that lead to death

    • E. 

      All of the above are reasons why Salmeterol exhibited asthma related deaths.

  • 13. 
    Which one of the following pairs are INCORRECTLY matched side effects and the receptors that cause them?
    • A. 

      Muscle tremor: beta 2 receptors

    • B. 

      Tachycardia: beta 1 receptors

    • C. 

      Palpitations: beta 2 receptors

    • D. 

      CNS effects (headache, nervousness): beta 2 receptors

    • E. 

      All the above are correctly matched side effects and receptor pairs

  • 14. 
    Anticholinergics exhibit all of the following actions except:
    • A. 

      Decrease vagal tone

    • B. 

      Decrease transmission of airway ganglion

    • C. 

      Decrease mucus production

    • D. 

      Decrease neurokinin release and inflammation

    • E. 

      All of the above are actions of anticholinergics

  • 15. 
    Anticholinergics act by antagonizing muscarinic acetylcholine receptors which ultimately ____ the Ca++ concentration and this ________ stimulation of MLCK.
    • A. 

      Increase; increase

    • B. 

      Increase; decrease

    • C. 

      Decrease; increase

    • D. 

      Decrease; decrease

  • 16. 
    Anticholinergics are thought to be especially useful in the management of _____ than it is at managing _____ because it blocks muscarinic receptors on bronchial smooth muscle, prevents muscle contraction, decreases mucus production versus allows bronchodilation.
    • A. 

      COPD; asthma

    • B. 

      Asthma; COPD

  • 17. 
    Anticholinergics have a unique structural feature that is responsible for its minimum systemic effects. What is this unique structural feature?
    • A. 

      Tropane ring structure

    • B. 

      Aromatic ring

    • C. 

      Long hydrocarbon tail

    • D. 

      Quaternary ammonium

  • 18. 
    Tiotropium is considered a more potent agent than ipratropium for which of the following TWO reasons?
    • A. 

      Less side effects

    • B. 

      Tighter binding

    • C. 

      More rapid onset

    • D. 

      Slower dissociation from M3

  • 19. 
    Methylxanthines like theophylline inhibit MLCK via which of the following mechanisms?
    • A. 

      Activation of the beta-2-receptors

    • B. 

      Stimulation of AC to increase cAMP

    • C. 

      Prevent the breakdown of cAMP

    • D. 

      Stimulation of MLC

    • E. 

      All of the above are actions of methylxanthines

  • 20. 
    Additional asthma/COPD benefits of methylxanthines include all of the following EXCEPT:
    • A. 

      Antagonist of adenosine

    • B. 

      Inhibitions of secretion of inflammatory mediators

    • C. 

      Inhibition of PKA

    • D. 

      Strengthens diaphragm

    • E. 

      All of the above are additional benefits of methylxanthines

  • 21. 
    Theophylline and aminophylline have very narrow therapeutic windows. Which of the following ranges of serum concentrations would you expect a patient to exhibit minor side effects such as N&V, nervousness, and insomnia?
    • A. 

      1-5 mcg/ml

    • B. 

      5-15 mcg/ml

    • C. 

      15-25 mcg/ml

    • D. 

      >25 mcg/ml

    • E. 

      Methylxanthine derivatives do not have narrow therapeutic indices

  • 22. 
    Roflumilast and cilomilast are PDE inhibitors of which of the following specific isoform?
    • A. 

      PDE3

    • B. 

      PDE4

    • C. 

      PDE5

    • D. 

      Roflumilast and cilomilast are not specific PDE inhibitors

  • 23. 
    Hormone synthesis in the adrenal cortex starts with _____, which is dependent on the ______ enzymes for transport into the inner mitochondrial membrane.
    • A. 

      Cholesterol; CYP11A1

    • B. 

      Pregnenolone; protein kinase A

    • C. 

      Progesterone; StAR

    • D. 

      Cholesterol; StAR

    • E. 

      Progesterone; CYP11A1

  • 24. 
    Diurnal production of cortisol exhibits all of the following patterns EXCEPT:
    • A. 

      Responds to sleep-wake cycles

    • B. 

      ACTH peaks in the morning

    • C. 

      Decreases with caffeine and exercise

    • D. 

      Cortisol peaks at 8 in the morning

    • E. 

      Brief bursts throughout the day

  • 25. 
    Treatment with exogenous glucocorticoids present a risk in changing the body's regulatory processes of making its own endogenous cortisol. Which of the following pairs are TWO properly matched treatment and effect?
    • A. 

      Sustained elevation = induced hypertrophy

    • B. 

      Sustained elevation = induced atrophy

    • C. 

      Prolonged exposure = induced hypertrophy

    • D. 

      Prolonged exposure = induced atrophy

Back to Top Back to top